PCN71 Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Who Have Received Two or More Prior Lines of Therapies
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.163
https://www.valueinhealthjournal.com/article/S1098-3015(21)00380-6/fulltext
Title :
PCN71 Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Who Have Received Two or More Prior Lines of Therapies
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00380-6&doi=10.1016/j.jval.2021.04.163
First page :
Section Title :
Open access? :
No
Section Order :
10741